Skip to main content

Advertisement

Table 4 Baseline levels of the measured markers according to clinical endpoint or no endpoint

From: vWF/ADAMTS13 is associated with on-aspirin residual platelet reactivity and clinical outcome in patients with stable coronary artery disease

  Endpoint (n = 73) No endpoint (n = 927) P-value§
vWF, % 113 (93, 141) 105 (81, 133) 0.032
ADAMTS-13 antigen, ng/mL 506 (452, 576) 533 (462, 607) 0.147
ADAMTS-13 activity, IU/mL 1.00 (0.73, 1.13) 1.03 (0.83, 1.19) 0.212
Ratio antigen 0.23 (0.17, 0.29) 0.20 (0.15, 0.26) 0.012
Ratio activity 119 (88, 175) 107 (77, 150) 0.051
Platelet count (× 109/L) 221 (181, 272) 228 (196, 263) 0.446
  1. Values are given as median (25th, 75th percentiles)
  2. § p-values refer to differences between the groups with high or low RPR
  3. Significant p-values are highlighted with boldface